Full Text of PDF (394k)
Article in Japanese
Abstract
Special Reports
Can mTOR inhibitor be used as the first-line drug for treatment of adult females with lymphangioleiomyomatosis?
Mie Hayashidaa Katsutoshi Andob Mitsuaki Sekiyab Kuniaki Seyamab Yoshikazu Inouec Koichiro Tatsumid the Respiratory Failure Research Group of the Ministry of Health, Labour and Welfare, Japan
aDivision of Respiratory Medicine, Infectious Diseases and Allergy, Department of Internal Medicine, Shinshu University Hospital
bDivision of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine
cClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center
dDepartment of Respirology, Graduate School of Medicine, Chiba University
ABSTRACT
Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, was approved as a pharmaceutical drug in 2014 and has begun being used in clinical practice in Japan. We reviewed the benefits and harm of mTOR inhibitor as a therapeutic drug for pulmonary lesions of LAM and summarized its clinical positioning. The body of evidence was evaluated and integrated by systematic reviews, and a recommendation was formulated based on methods described in “Medical Information Network Distribution Service (Minds) Handbook for CPG Development 2014” by the Japan Council for Quality Health Care.
KEYWORDS
Lymphangioleiomyomatosis mTOR inhibitor Sirolimus Systematic review Minds
Received 18 Feb 2016 ／ Accepted 24 Mar 2016
AJRS, 5(4): 166-171, 2016
Copyright © The Japanese Respiratory Society All Rights Reserved.